ACKR1 (Atypical Chemokine Receptor 1)

Collectively, these findings indicate that as CRC advances, increased secretion of CXCL2 from malignant cells stimulates ACKR1 on ECs, thereby promoting tumor invasion and metastasis. This study provides a framework for stage-specific interventions, particularly for locally advanced CRC, by disrupting ACKR1 on ECs within TME to impede metastasis and improve clinical outcomes.

Multimodal cell-cell interaction analysis and functional experiments demonstrate that HEV expressed VCAM1 and ICAM1 recruits and activates CXCL13+ TLC through the CXCL13-ACKR1 pathway, which promotes TLS formation via CXCL13-CXCR5-dependent crosstalk with B lymphocytes. We further develop a single-cell/spatial TLS signature that captures the cellular ecosystem of iTLS-containing tumor, demonstrating predictive value for immunotherapy outcomes in GC patients.

The competitive receptor ACKR1 was minimally expressed on endothelial cells, consistent with PDAC hypo-vascularity...Differential interactions and the presence of "dominant signaling cell populations " with dominant outgoing signals may underlie the heterogeneity in tumor aggressiveness across these cancers. Comparative scRNA-seq analysis of multiple cancers reveals distinct tumor phenotypes and cell-cell communication patterns, offering insights into the molecular architecture of human solid tumors.

We further validated that endothelial cells (ECs), when stimulated by IFNγ, potentially released by CD8+ T cells, acquire an enhanced ability for presenting antigens and activating CD8+ T cells. Together, our study systematically characterizes the TME dynamics and uncovers the unique interaction between activated CD8+ T cells and ECs after TNT.

Given its potential as a biomarker and therapeutic target, further investigation into DARC's mechanisms may reveal new strategies for cancer prevention and treatment. Overall, ACKR1 is a promising area of research, providing information about the interplay between inflammation, tumor progression, and immune surveillance.

In conclusion, this study highlights the prognostic and immunological implications of TLS heterogeneity in PCa, demonstrating that the spatial distribution and maturity of TLSs are closely linked to TME activation and improved clinical outcomes. These findings provide novel insights into the immune landscape of PCa and establish a foundation for immune-based precision stratification and therapeutic development.

Recent research has unveiled its diverse functions beyond malaria like susceptibility in inflammation, cancer biology, hematopoiesis, and several diseases. This perspective highlights these emerging roles and their potential therapeutic applications.

Our findings reveal complex interactions between DARC and these molecular markers, suggesting their synergistic roles in promoting or repressing breast cancer progression. Understanding these relationships could lead to developing more effective and personalized therapeutic strategies.

Our analysis combining bulk and single-cell transcriptomics provides a multi-scale view of PDAC pathogenesis. The findings highlight the interplay between ncRNAs, hub genes, and cellular crosstalk in shaping the tumor ecosystem and suggest novel targets for precision therapeutic intervention and biomarker development.

Although the 'Duffy-null' allele has been the focus of research as a contributor to aggressive breast cancer in Black women, this study with 34,930 cases and controls found no associations with risk.

SAA significantly enhances the efficacy of anti-PD-1 therapy by promoting HEV-mediated stem-like CD8 T cells infiltration in TNBC. The combination of SAA and αPD-1 represents a promising therapeutic strategy that warrants further exploration in preclinical and clinical settings.

Notably, tumor-specific intercellular signaling pathways, such as CSF1/CSF1R and CXCL/ACKR1, were identified, highlighting their potential role in fostering an immunosuppressive TME. Our findings unveil a distinct pattern of crosstalk between FAP+ fibroblasts and SPP1+ macrophages in PCa, shedding light on potential therapeutic targets for advanced PCa.